Literature DB >> 9724792

Conversion of a radioresistant phenotype to a more sensitive one by disabling erbB receptor signaling in human cancer cells.

D M O'Rourke1, G D Kao, N Singh, B W Park, R J Muschel, C J Wu, M I Greene.   

Abstract

Inhibition of cell growth and transformation can be achieved in transformed glial cells by disabling erbB receptor signaling. However, recent evidence indicates that the induction of apoptosis may underlie successful therapy of human cancers. In these studies, we examined whether disabling oncoproteins of the erbB receptor family would sensitize transformed human glial cells to the induction of genomic damage by gamma-irradiation. Radioresistant human glioblastoma cells in which erbB receptor signaling was inhibited exhibited increased growth arrest and apoptosis in response to DNA damage. Apoptosis was observed after radiation in human glioma cells containing either a wild-type or mutated p53 gene product and suggested that both p53-dependent and -independent mechanisms may be responsible for the more radiosensitive phenotype. Because cells exhibiting increased radiation-induced apoptosis were also capable of growth arrest in serum-deprived conditions and in response to DNA damage, apoptotic cell death was not induced simply as a result of impaired growth arrest pathways. Notably, inhibition of erbB signaling was a more potent stimulus for the induction of apoptosis than prolonged serum deprivation. Proximal receptor interactions between erbB receptor members thus influence cell cycle checkpoint pathways activated in response to DNA damage. Disabling erbB receptors may improve the response to gamma-irradiation and other cytotoxic therapies, and this approach suggests that present anticancer strategies could be optimized.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9724792      PMCID: PMC27983          DOI: 10.1073/pnas.95.18.10842

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  41 in total

1.  Effects of ectopic overexpression of p21(WAF1/CIP1) on aneuploidy and the malignant phenotype of human brain tumor cells.

Authors:  J Chen; T Willingham; M Shuford; D Bruce; E Rushing; Y Smith; P D Nisen
Journal:  Oncogene       Date:  1996-10-03       Impact factor: 9.867

2.  Neu differentiation factor (Heregulin) activates a p53-dependent pathway in cancer cells.

Authors:  S S Bacus; Y Yarden; M Oren; D M Chin; L Lyass; C R Zelnick; A Kazarov; W Toyofuku; J Gray-Bablin; R R Beerli; N E Hynes; M Nikiforov; R Haffner; A Gudkov; K Keyomarsi
Journal:  Oncogene       Date:  1996-06-20       Impact factor: 9.867

3.  Transformational and altered signal transduction by a naturally occurring mutant EGF receptor.

Authors:  D K Moscatello; R B Montgomery; P Sundareshan; H McDanel; M Y Wong; A J Wong
Journal:  Oncogene       Date:  1996-07-04       Impact factor: 9.867

4.  Enhanced tumorigenic behavior of glioblastoma cells expressing a truncated epidermal growth factor receptor is mediated through the Ras-Shc-Grb2 pathway.

Authors:  S A Prigent; M Nagane; H Lin; I Huvar; G R Boss; J R Feramisco; W K Cavenee; H S Huang
Journal:  J Biol Chem       Date:  1996-10-11       Impact factor: 5.157

5.  p53-dependent G1 arrest and p53-independent apoptosis influence the radiobiologic response of glioblastoma.

Authors:  D A Haas-Kogan; G Yount; M Haas; D Levi; S S Kogan; L Hu; C Vidair; D F Deen; W C Dewey; M A Israel
Journal:  Int J Radiat Oncol Biol Phys       Date:  1996-08-01       Impact factor: 7.038

6.  Regulation of radiation-induced apoptosis in oncogene-transfected fibroblasts: influence of H-ras on the G2 delay.

Authors:  W G McKenna; E J Bernhard; D A Markiewicz; M S Rudoltz; A Maity; R J Muschel
Journal:  Oncogene       Date:  1996-01-18       Impact factor: 9.867

7.  Mice lacking p21CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control.

Authors:  C Deng; P Zhang; J W Harper; S J Elledge; P Leder
Journal:  Cell       Date:  1995-08-25       Impact factor: 41.582

8.  p53 mutations, O6-alkylguanine DNA alkyltransferase activity, and sensitivity to procarbazine in human brain tumors.

Authors:  S J Russell; Y W Ye; P G Waber; M Shuford; S C Schold; P D Nisen
Journal:  Cancer       Date:  1995-03-15       Impact factor: 6.860

9.  Gamma-radiation-induced apoptosis in human colorectal adenoma and carcinoma cell lines can occur in the absence of wild type p53.

Authors:  T S Bracey; J C Miller; A Preece; C Paraskeva
Journal:  Oncogene       Date:  1995-06-15       Impact factor: 9.867

Review 10.  A tiger behind many doors: multiple genetic pathways to malignant glioma.

Authors:  D N Louis; J F Gusella
Journal:  Trends Genet       Date:  1995-10       Impact factor: 11.639

View more
  17 in total

Review 1.  ErbB receptors: from oncogenes to targeted cancer therapies.

Authors:  Hongtao Zhang; Alan Berezov; Qiang Wang; Geng Zhang; Jeffrey Drebin; Ramachandran Murali; Mark I Greene
Journal:  J Clin Invest       Date:  2007-08       Impact factor: 14.808

2.  Structural insights into the down-regulation of overexpressed p185(her2/neu) protein of transformed cells by the antibody chA21.

Authors:  Huihao Zhou; Zhao Zha; Yang Liu; Hongtao Zhang; Juanjuan Zhu; Siyi Hu; Guodong Shen; Liansheng Cheng; Liwen Niu; Mark I Greene; Maikun Teng; Jing Liu
Journal:  J Biol Chem       Date:  2011-06-16       Impact factor: 5.157

3.  RNA aptamers and their therapeutic and diagnostic applications.

Authors:  Katherine Germer; Marissa Leonard; Xiaoting Zhang
Journal:  Int J Biochem Mol Biol       Date:  2013-03-31

Review 4.  Exciting new advances in neuro-oncology: the avenue to a cure for malignant glioma.

Authors:  Erwin G Van Meir; Costas G Hadjipanayis; Andrew D Norden; Hui-Kuo Shu; Patrick Y Wen; Jeffrey J Olson
Journal:  CA Cancer J Clin       Date:  2010 May-Jun       Impact factor: 508.702

Review 5.  Reversion of the ErbB malignant phenotype and the DNA damage response.

Authors:  E Aaron Runkle; Hongtao Zhang; Zheng Cai; Zhiqiang Zhu; Barry L Karger; Shiaw-Lin Wu; Donald M O'Rourke; Zhaocai Zhou; Qiang Wang; Mark I Greene
Journal:  Exp Mol Pathol       Date:  2012-09-27       Impact factor: 3.362

6.  A phase I and biology study of gefitinib and radiation in children with newly diagnosed brain stem gliomas or supratentorial malignant gliomas.

Authors:  J Russell Geyer; Clinton F Stewart; Mehmet Kocak; Alberto Broniscer; Peter Phillips; James G Douglas; Susan M Blaney; Roger J Packer; Sri Gururangan; Anu Banerjee; Mark W Kieran; Larry E Kun; Richard J Gilbertson; James M Boyett
Journal:  Eur J Cancer       Date:  2010-08-12       Impact factor: 9.162

7.  A phase II study of gefitinib and irradiation in children with newly diagnosed brainstem gliomas: a report from the Pediatric Brain Tumor Consortium.

Authors:  Ian F Pollack; Clinton F Stewart; Mehmet Kocak; Tina Young Poussaint; Alberto Broniscer; Anu Banerjee; James G Douglas; Larry E Kun; James M Boyett; J Russell Geyer
Journal:  Neuro Oncol       Date:  2011-02-03       Impact factor: 12.300

Review 8.  Molecularly targeted therapies for malignant glioma: rationale for combinatorial strategies.

Authors:  Nikhil G Thaker; Ian F Pollack
Journal:  Expert Rev Neurother       Date:  2009-12       Impact factor: 4.618

9.  Molecular pharmacodynamics of PM02734 (elisidepsin) as single agent and in combination with erlotinib; synergistic activity in human non-small cell lung cancer cell lines and xenograft models.

Authors:  Yi-He Ling; Miguel Aracil; José Jimeno; Roman Perez-Soler; Yiyu Zou
Journal:  Eur J Cancer       Date:  2009-04-05       Impact factor: 9.162

10.  Radiation-induced Akt activation modulates radioresistance in human glioblastoma cells.

Authors:  Hui-Fang Li; Jung-Sik Kim; Todd Waldman
Journal:  Radiat Oncol       Date:  2009-10-14       Impact factor: 3.481

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.